Overview

Biomarker and Genetic Predictors of Erenumab Treatment Response

Status:
Recruiting
Trial end date:
2022-12-14
Target enrollment:
Participant gender:
Summary
To explore the relationship between clinical response to erenumab and genetic biomarkers
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Erenumab